Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways

• DOI: 10.3389/fphar.2021.664697
• Publication Date: 2021-06-14T12:16:02Z
• Authors: Xue Yang; Jiamin Liang; Ziyi Wang; Yuangang Su; Yunfei Zhan; Zuoxing Wu; Jing Li; Xuedong Li; Runfeng Chen; Jinmin Zhao; Jiake Xu; Qian Liu; Bo Zhou
• Keywords: Bone remodeling

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology. Postmenopausal osteoporosis (PMOP), which increases risk fracture, is most common bone disease women. PMOP not only death but also imposes financial burden on countless families. At present, drugs used treat have significant side effects, so it important find effective anti-osteoporosis medications without major effects. Sesamolin (Ses) kind natural lignan extracted from sesame oil. Many researches shown that Ses has anti-inflammatory, antioxidative, anticancer however still unknown whether any effect osteoporosis. In this research, we explored therapeutic process osteoclast formation resorption found effectively inhibited vitro through TRAcP staining hydroxyapatite assays. Through Western blot analysis NF-κB pathway, MAPK c-Fos NFATc1, activation signaling pathways induced by RANKL significantly reduced protein expression NFATc1. Several genes specifically expressed osteoclasts were determined qPCR, play inhibitory role these genes. Besides, an model ovariectomized (OVX) mice employed verify could reduce loss caused estrogen deficiency vivo . conclusion, showed promise as new treatment for postmenopausal